<SEC-DOCUMENT>0001104659-25-094747.txt : 20250930
<SEC-HEADER>0001104659-25-094747.hdr.sgml : 20250930
<ACCEPTANCE-DATETIME>20250930073324
ACCESSION NUMBER:		0001104659-25-094747
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250930
DATE AS OF CHANGE:		20250930

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LAVA Therapeutics NV
		CENTRAL INDEX KEY:			0001840748
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40241
		FILM NUMBER:		251358162

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		YALELAAN 62
		CITY:			UTRECHT
		PROVINCE COUNTRY:   	P7
		BUSINESS PHONE:		31 6 3000 3035

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		YALELAAN 62
		CITY:			UTRECHT
		PROVINCE COUNTRY:   	P7

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LAVA Therapeutics BV
		DATE OF NAME CHANGE:	20210115
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>tm2526706d3_defa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 14A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(RULE 14a-101)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN PROXY STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 14A INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proxy Statement Pursuant to Section&nbsp;14(a)&nbsp;of
the</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 5%">&nbsp;</TD>
  <TD STYLE="width: 95%">Filed by the Registrant&ensp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 5%">&nbsp;</TD>
  <TD STYLE="width: 95%">Filed by a Party other than the Registrant&ensp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Check the appropriate box:</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary Proxy Statement</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Confidential, for Use of the Commission Only (as permitted by Rule&nbsp;14a-6(e)(2))</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive Proxy Statement</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive Additional Materials</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting Material Pursuant to &sect;240.14a-12</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LAVA Therapeutics N.V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Registrant as Specified In Its Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Person(s)&nbsp;Filing Proxy Statement,
if other than the Registrant)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">Payment of Filing Fee (Check the appropriate
box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No fee required.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; padding-left: 10pt; font-size: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee paid previously with preliminary materials.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee computed on table in exhibit required by Item 25(b)&nbsp;per Exchange Act Rules&nbsp;14a6(i)(1)&nbsp;and 0-11</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&#160;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&#160;8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&#160;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&#160;13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of The Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event reported)<BR>

September 30, 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&#160;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>


<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LAVA Therapeutics N.V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified in its
charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&#160;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 33%"><B>The Netherlands</B></TD>
    <TD STYLE="text-align: center; width: 33%"><B>001-40241</B></TD>
    <TD STYLE="text-align: center; width: 34%"><B>82-2745484</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B>(State or other jurisdiction<BR>
 of incorporation)</B></TD>
    <TD STYLE="text-align: center"><B>(Commission <BR>
File Number)</B></TD>
    <TD STYLE="text-align: center"><B>(IRS Employer<BR>
 Identification No.)</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: center; vertical-align: top; width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Yalelaan
    62</B> <B>Utrecht</B><B>, The Netherlands</B></P></TD>
    <TD STYLE="vertical-align: bottom; width: 50%; font-size: 10pt; text-align: center"><B>3584</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><B>(Address of principal executive offices)</B></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><B>(Zip Code)</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>+31 85 016 3100</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Registrant&#8217;s telephone number, including
area code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Former name or former address, if changed
since last report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&#160;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form&#160;8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD>Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD>Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD>Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD>Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><B>Title of each class</B></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><B>Trading&#8239;Symbol(s)</B></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><B>Name of each exchange on which registered</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><B>Common shares, nominal value &#8364;0.12 per share</B></TD>
    <TD STYLE="text-align: center"><B>LVTX</B></TD>
    <TD STYLE="text-align: center"><B>NASDAQ Global Select Market</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Emerging growth company <FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section&#160;13(a)&#160;of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Item 8.01 Other Events.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, LAVA Therapeutics N.V. (the &#8220;Company&#8221;)
issued a press release announcing its intention to cancel the Extraordinary General Meeting of Shareholders (the &#8220;EGM&#8221;) scheduled
to occur on September 30, 2025 to consider and approve certain matters related to the Company&#8217;s previously announced transaction
with XOMA Royalty Corporation (&#8220;XOMA&#8221;), pursuant to which XOMA made an offer to purchase all of the issued and outstanding
common shares in the capital of the Company (the &#8220;Transaction&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The EGM is expected to be reconvened by early
November 2025. The meeting date, record date and location for the reconvened EGM will be determined and announced by the Company at a
later date. Votes already cast by shareholders in respect of the EGM will not count towards the voting outcome on the matters proposed
to the reconvened EGM. Shareholders as of the record date for the reconvened EGM will have to cast their votes (or cast their votes again,
as the case may be) for their votes to count towards the voting outcome. A copy of the press release is attached hereto as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Item 9.01 Financial Statements and Exhibits.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><B>Exhibit No.</B></TD>
    <TD STYLE="width: 2%">&#160;</TD>
    <TD STYLE="width: 88%"><B>Description</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="#a_001">99.1</A></TD>
    <TD>&#160;</TD>
    <TD><A HREF="#a_001">Press Release dated September 30, 2025.</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>104</TD>
    <TD>&#160;</TD>
    <TD>Cover page interactive data file (embedded within the inline XBRL document).</TD></TR>
  </TABLE>
<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-style: normal"><B>Cautionary
Note Regarding Forward-Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Current Report on Form 8-K contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#8220;anticipate&#8221;, &#8220;believe&#8221;,
 &#8220;could&#8221;, &#8220;will&#8221;, &#8220;may&#8221;, &#8220;expect&#8221;, &#8220;should&#8221;, &#8220;plan&#8221;, &#8220;intend&#8221;,
 &#8220;estimate&#8221;, &#8220;potential&#8221;, &#8220;suggests&#8221;, and similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements
are based on the Company&#8217;s expectations and assumptions as of the date of this Form 8-K and are subject to various risks and uncertainties
that may cause actual results to differ materially from these forward-looking statements. As a result, a number of important factors could
cause actual results to differ materially from those indicated by such forward-looking statements, including: the risk that the Transaction
may not be completed in a timely manner, or at all, which may adversely affect the Company&#8217;s business and the price of its common
shares; the risk that the terms of the Transaction may be revised to be less favorable to the Company&#8217;s shareholders; the delay
or failure of the terms of the Transaction to be revised or of the offer conditions to be satisfied (or waived), including insufficient
common shares of the Company being tendered in the offer, any of which delays may impact the amount payable to the Company&#8217;s shareholders
in the Transaction; the possibility that competing offers will be made; significant costs associated with the Transaction; the risk that
any shareholder or other litigation in connection with the Transaction may result in significant costs of defense, indemnification and
liability; the risk that activities related to the CVR agreement may not result in any value to the Company&#8217;s shareholders; the
possibility that prior to the completion of the Transaction, the Company&#8217;s or XOMA&#8217;s business may experience significant disruptions
due to transaction-related uncertainty; the effects of disruption from the transactions of the Company&#8217;s business and the fact that
the announcement and pendency of the Transaction may make it more difficult to establish or maintain relationships with employees, manufacturers,
suppliers, vendors or business partners; the occurrence of any event, change or other circumstance that could give rise to the termination
of the purchase agreement; as well as potential adverse effects on the Company&#8217;s business condition and results from general economic
and market conditions and overall fluctuations in the United States and international equity markets, including as a result of inflation,
heightened interest rates, recent and potential future pandemics and other health crises, and hostilities, including the Russian invasion
of Ukraine and the conflict in the Middle East. These and other risks are described in greater detail under the caption &#8220;Risk Factors&#8221;
in the Company&#8217;s most recent Annual Report on Form 10-K and other filings the Company makes with the U.S. Securities and Exchange
Commission (the &#8220;SEC&#8221;). The Company assumes no obligation to update any forward-looking statements contained herein whether
as a result of any new information, future events, change in expectations or otherwise, except as otherwise required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-style: normal"><B>Additional
Information and Where to Find It</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the proposed Transaction between
the Company and XOMA, XOMA filed a Tender Offer Statement on Schedule TO with the SEC and the Company filed a Solicitation/Recommendation
Statement on Schedule 14D-9 with the SEC related to the tender offer. The Company also filed a proxy statement in connection with the
originally scheduled EGM at which the Company shareholders were requested to vote on certain proposed resolutions (the &#8220;EGM Proposals&#8221;)
in connection with the Transaction. The Company plans to send a revised proxy statement and proxy card to each shareholder entitled to
vote at the reconvened extraordinary general meeting. <B>INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REVISED PROXY STATEMENT
REGARDNG THE EXTRAORDINARY GENERAL MEETING AND THE TENDER OFFER MATERIALS (INCLUDING THE OFFER TO PURCHASE, A LETTER OF TRANSMITTAL AND
RELATED DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 REGARDING THE OFFER, AS THEY MAY BE AMENDED OR SUPPLEMENTED
FROM TIME TO TIME, BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND SECURITY HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION
REGARDING TENDERING THEIR SHARES (INCLUDING THE TERMS AND CONDITIONS OF THE OFFER) OR MAKING ANY VOTING DECISION FOR THE EXTRAORDINARY
GENERAL MEETING. </B>Investors and security holders may obtain a free copy of these statements and other documents filed with the SEC
at the website maintained by the SEC at <FONT STYLE="text-decoration: underline">www.sec.gov</FONT> or by directing such requests to the information agent for the Offer, which
will be named in the tender offer statement. Investors and security holders may also obtain, at no charge, the documents filed or furnished
to the SEC by LAVA under the &#8220;SEC Filings&#8221; subsection of the &#8220;Financials &amp; Filings&#8221; section of the Company&#8217;s
website at <FONT STYLE="text-decoration: underline">https://ir.lavatherapeutics.com</FONT> or by accessing the Investor Relations sections of XOMA&#8217;s website at <FONT STYLE="text-decoration: underline">https://www.investors.xoma.com</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Participants in the Solicitation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, its directors and executive officers,
and other members of its management and employees, as well as XOMA and its directors and executive officers, may be deemed to be participants
in the solicitation of proxies from the Company&#8217;s shareholders in connection with the EGM Proposals. Information about the Company&#8217;s
directors and executive officers and their ownership of Shares is set forth in the proxy statement for the Company&#8217;s 2025 annual
general meeting of shareholders, which was filed with the SEC on April 28, 2025. Information about XOMA&#8217;s directors and executive
officers is set forth in the proxy statement for XOMA&#8217;s 2025 annual meeting of shareholders, which was filed with the SEC on April
15, 2025. Shareholders may obtain additional information regarding the direct and indirect interests of the participants in the solicitation
of proxies in connection with the EGM Proposals, including the interests of the Company&#8217;s directors and executive officers in the
Transaction, which may be different than those of the Company&#8217;s shareholders generally, by reading the proxy statement and other
relevant documents regarding the Transaction which will be filed with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR>
<TD STYLE="font-size: 10pt">&#160;</TD>
<TD COLSPAN="2" STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LAVA Therapeutics N.V.</B></FONT></TD></TR>
<TR>
<TD STYLE="font-size: 10pt">&#160;</TD>
<TD COLSPAN="2" STYLE="font-size: 10pt">&#160;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; width: 50%; padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: September 30, 2025</FONT></TD>
<TD STYLE="vertical-align: bottom; width: 5%; padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; width: 45%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Fred Powell</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; font-size: 10pt">&#160;</TD>
<TD STYLE="vertical-align: bottom">&#160;</TD>
<TD STYLE="vertical-align: bottom">Fred Powell</TD></TR>
<TR>
<TD STYLE="vertical-align: top; font-size: 10pt">&#160;</TD>
<TD STYLE="vertical-align: bottom">&#160;</TD>
<TD STYLE="vertical-align: bottom">Chief Financial Officer</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_001"></A>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2526706d2_ex99-1img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 13pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>
LAVA Therapeutics to Move Extraordinary General Meeting<BR>
to Early November 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Additional time enables LAVA Therapeutics to
address potential liabilities and confirm net cash to be delivered to Shareholders. LAVA Therapeutics and XOMA Royalty anticipate closing
the announced acquisition in the fourth quarter of 2025.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>UTRECHT, The Netherlands, and PHILADELPHIA, Penn, September 30,
2025 (GLOBE NEWSWIRE)</B> &ndash; LAVA Therapeutics N.V. (the &ldquo;Company&rdquo;) (NASDAQ: LVTX) today announced that the Company has
decided to cancel the Extraordinary General Meeting of Shareholders (the &ldquo;EGM&rdquo;)&nbsp;scheduled to occur on September&nbsp;30,
2025 to consider and approve certain matters related to the Company&rsquo;s previously announced transaction with XOMA Royalty Corporation
(&ldquo;XOMA&rdquo;), pursuant to which XOMA made an offer to purchase all of the issued and outstanding common shares in the capital
of the Company (the &ldquo;Transaction&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company is canceling the EGM to continue discussions with XOMA
concerning the terms of the Transaction, including the Company&rsquo;s estimated cash forecast and the consideration payable to the Company&rsquo;s
shareholders in the Transaction. Both the Company and XOMA Royalty remain committed to completing the Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We are committed to closing this transaction and look forward
to working collaboratively with the LAVA team to further define LAVA&rsquo;s cash forecast in an effort to close this transaction in an
expeditious manner&rdquo; stated Owen Hughes, CEO of XOMA Royalty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The EGM is expected to be reconvened by early November 2025. The meeting
date, record date and location for the reconvened EGM will be determined and announced by the Company at a later date. Votes already cast
by shareholders in respect of the EGM will not count towards the voting outcome on the matters proposed to the reconvened EGM. Shareholders
as of the record date for the reconvened EGM will have to cast their votes (or cast their votes again, as the case may be) for their votes
to count towards the voting outcome.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About LAVA Therapeutics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LAVA Therapeutics N.V. is a biopharmaceutical company that has developed
several clinical-stage bispecific gamma delta T cell engagers using its proprietary Gammabody<FONT STYLE="font-size: 10pt"><SUP>&reg;</SUP></FONT>
platform, including JNJ-89853413, targeting CD33 and hematologic cancers (NCT06618001), partnered with Johnson &amp; Johnson, and PF-08046052,
targeting EGFR and solid tumors (NCT05983133), partnered with Pfizer, Inc. For more information on LAVA, please visit <U>www.lavatherapeutics.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gammabody<FONT STYLE="font-size: 10pt"><SUP>&reg;</SUP></FONT> is a
registered trademark of LAVA Therapeutics N.V.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Cautionary Note on Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Words such as &ldquo;anticipate&rdquo;, &ldquo;believe&rdquo;, &ldquo;could&rdquo;,
 &ldquo;will&rdquo;, &ldquo;may&rdquo;, &ldquo;expect&rdquo;, &ldquo;should&rdquo;, &ldquo;plan&rdquo;, &ldquo;intend&rdquo;, &ldquo;estimate&rdquo;,
 &ldquo;potential&rdquo;, &ldquo;suggests&rdquo;, and similar expressions (as well as other words or expressions referencing future events,
conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on the Company&rsquo;s
expectations and assumptions as of the date of this press release and are subject to various risks and uncertainties that may cause actual
results to differ materially from these forward-looking statements. As a result, a number of important factors could cause actual results
to differ materially from those indicated by such forward-looking statements, including: the risk that the Transaction may not be completed
in a timely manner, or at all, which may adversely affect the Company&rsquo;s business and the price of its common shares; the risk that
the terms of the Transaction may be revised to be less favorable to the Company&rsquo;s shareholders; the delay or failure of the terms
of the Transaction to be revised or of the offer conditions to be satisfied (or waived), including insufficient common shares of the Company
being tendered in the offer, any of which delays may impact the amount payable to the Company&rsquo;s shareholders in the Transaction;
the possibility that competing offers will be made; significant costs associated with the Transaction; the risk that any shareholder or
other litigation in connection with the Transaction may result in significant costs of defense, indemnification and liability; the risk
that activities related to the CVR agreement may not result in any value to the Company&rsquo;s shareholders; the possibility that prior
to the completion of the Transaction, the Company&rsquo;s or XOMA&rsquo;s business may experience significant disruptions due to transaction-related
uncertainty; the effects of disruption from the transactions of the Company&rsquo;s business and the fact that the announcement and pendency
of the Transaction may make it more difficult to establish or maintain relationships with employees, manufacturers, suppliers, vendors
or business partners; the occurrence of any event, change or other circumstance that could give rise to the termination of the purchase
agreement; as well as potential adverse effects on the Company&rsquo;s business condition and results from general economic and market
conditions and overall fluctuations in the United States and international equity markets, including as a result of inflation, heightened
interest rates, recent and potential future pandemics and other health crises, and hostilities, including the Russian invasion of Ukraine
and the conflict in the Middle East. These and other risks are described in greater detail under the caption &ldquo;Risk Factors&rdquo;
in the Company&rsquo;s most recent Annual Report on Form 10-K and other filings the Company makes with the U.S. Securities and Exchange
Commission (the &ldquo;SEC&rdquo;). The Company assumes no obligation to update any forward-looking statements contained herein whether
as a result of any new information, future events, change in expectations or otherwise, except as otherwise required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Additional Information and Where to Find It</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The description contained in this press release is for informational
purposes only and is not a recommendation, an offer to buy or the solicitation of an offer to sell any shares of the Company&rsquo;s common
shares. XOMA filed a Tender Offer Statement on Schedule TO with the SEC and the Company filed a Solicitation/Recommendation Statement
on Schedule 14D-9 with the SEC related to the tender offer. The Company also filed a proxy statement in connection with the originally
scheduled EGM at which the Company shareholders were requested to vote on certain proposed resolutions (the &ldquo;EGM Proposals&rdquo;)
in connection with the Transactions. The Company plans to send a revised proxy statement and proxy card to each shareholder entitled to
vote at the reconvened extraordinary general meeting. <B>INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REVISED PROXY STATEMENT
REGARDNG THE EXTRAORDINARY GENERAL MEETING AND THE TENDER OFFER MATERIALS (INCLUDING THE OFFER TO PURCHASE, A LETTER OF TRANSMITTAL AND
RELATED DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 REGARDING THE OFFER, AS THEY MAY BE AMENDED OR SUPPLEMENTED
FROM TIME TO TIME, BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND SECURITY HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION
REGARDING TENDERING THEIR SHARES (INCLUDING THE TERMS AND CONDITIONS OF THE OFFER) OR MAKING ANY VOTING DECISION FOR THE EXTRAORDINARY
GENERAL MEETING. </B>Investors and security holders may obtain a free copy of these statements and other documents filed with the SEC
at the website maintained by the SEC at <U>www.sec.gov</U> or by directing such requests to the information agent for the Offer, which
will be named in the tender offer statement. Investors and security holders may also obtain, at no charge, the documents filed or furnished
to the SEC by LAVA under the &ldquo;SEC Filings&rdquo; subsection of the &ldquo;Financials &amp; Filings&rdquo; section of the Company&rsquo;s
website at <U>https://ir.lavatherapeutics.com</U> or by accessing the Investor Relations sections of XOMA&rsquo;s website at <U>https://www.investors.xoma.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Participants in the Solicitation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company, its directors and executive officers, and other members
of its management and employees, as well as XOMA and its directors and executive officers, may be deemed to be participants in the solicitation
of proxies from the Company&rsquo;s shareholders in connection with the EGM Proposals. Information about the Company&rsquo;s directors
and executive officers and their ownership of Shares is set forth in the proxy statement for the Company&rsquo;s 2025 annual general meeting
of shareholders, which was filed with the SEC on April 28, 2025. Information about XOMA&rsquo;s directors and executive officers is set
forth in the proxy statement for XOMA&rsquo;s 2025 annual meeting of shareholders, which was filed with the SEC on April 15, 2025. Shareholders
may obtain additional information regarding the direct and indirect interests of the participants in the solicitation of proxies in connection
with the EGM Proposals, including the interests of the Company&rsquo;s directors and executive officers in the Transaction, which may
be different than those of the Company&rsquo;s shareholders generally, by reading the proxy statement and other relevant documents regarding
the Transaction which will be filed with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>LAVA Therapeutics Investor Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fred Powell</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LAVA Therapeutics</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1 800-311-6892</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ir@lavatherapeutics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2526706d2_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2526706d2_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !Q 0H# 2(  A$! Q$!_\0
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M\=A11161Q!1110!C^*-;3P_X=O-1?!:-,1J?XG/"C\Z\'\$Z"WBSQ8J7>Z2
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MA3.!^0Y/XU=*-W=]#JP5-2J<\MHZGHGP;T#R;.YUV9/GF/DP9'\ ^\?Q/'_
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MHX;]Y*SNSCA+DXKH=)\)ZSJNUDMC#"?^6DWRC\!U->FZ1X1T;1P&M[4-*/\
MEK+\S?KT_"MP  55/+EO-G/B,ZD]*,;>;..TKX>Z?:!7O9&NY/[I^5!^'?\
M.NM@MH;6(101)&@Z*BX J6BO1IT84U:*/$JUZE5WF[ABBBBM3$*X?XL_\B'<
M?]=H_P#T*NXKF_'.@W7B3PS+IMF\*3/(C S,0N <]@:J+LT:T9*-2+?<\H^%
M6M:=HFLWTNI7<=M') %5GZ$[AQ7J_P#PG_A7_H-VWYG_  KRW_A37B/_ )^M
M,_[^O_\ $4?\*9\1_P#/UIG_ ']?_P"(K>2A)WN>E6CAJL^=S/4O^$_\*_\
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M&A+XB\,W=A@>:5WPD]G'(_P^A-?/>BZ_?^&Y+]+?*-<P-;R \%3Z_4<_G7U
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M<0A-HD!*\N!R 1V-4XV=C1TVFHF_17+>)O$SZ5X/FU2SEMGNU1&",=PR2 >
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MW"BBBD0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
K!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
